Iron Overload Clinical Trial
Official title:
Iron Metabolism in Small Pre Term Newborns
Iron is an essential micronutrient that plays an important role in cellular functions of all
microorganisms. Both iron deficiency and iron excess during the early weeks of life can have
severe effects on neurodevelopment that may persist into adulthood and may not be corrected
by restoration of normal iron levels.
Iron overload remains a significant concern in preterm infants because they have low levels
of iron-binding proteins and immature antioxidant systems.
The aim of the study is to evaluate if iron supplementation is required/necessary in VLBW
Very Low Birth Weight (less than 1500 grams) and to assess the efficacy and safety of the
iron supplementation practice for VLBW preterm infants as implemented in the Neonatal
Intensive Care Unit (NICU) at the Ha'Emek Medical Center, Afula, Israel.
Primary objectives
1. The aim of the study is to investigate the presence and level of Cryptic LPI in pre term
infants plasma before and during enteral iron supplementation.
2. To assess the iron status in preterm infants and correlated them with clinical
parameters: the blood transfusions given and the amount of blood obtained for routine
laboratory analysis, and amount of daily iron intake through diet (human milk or
formula)
3. To identify which preterm infants are at risk for iron deficiency or iron overload.
4. To investigate laboratory tests, Hepcidin and CHr, for the assessment of iron metabolism
in preterm infants.
Secondary objectives To review the current guidelines in use for monitoring iron status and
prevention of iron deficiency in VLWP.
To implement future new guidelines for monitoring iron therapy and iron supplementation in
pre terms infants if the results suggest changes in the current policy.
Treatment guidelines:
Erythropoietin will not be administrated. Restrictive red cell transfusion guidelines will be
followed. All the premature infants included in the study will receive Vitamin E
supplementation as the currently used in the NICU ward.
Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4
weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together
with the first morning meal
Patients and Methods Study population: all newborn infants VLBW and or borne at 30 weeks or
less of gestational age admitted at the Ha'Emek Medical Center, NICU will be screened for
study eligibility. The estimate number of patients that will be included in the study is 50
during a period of one year
Inclusion criteria:
VLBW and / or borne at 30 weeks or less of gestational age that are scheduled to receive
enteral iron supplementation as part of the standard protocol currently used by the NICU.
Birth weight will be not an inclusion or exclusion criteria for preterms born at 30 weeks or
less.
Exclusion criteria: Major physical anomalies, renal or cardiac diseases, newborns that
underwent major surgery during the study period, acute or chronic fetal blood loss, hemolytic
anemia, refusal to receive parental consent.
Laboratory analyses:
Complete blood count including reticulocyte count and CHr. Serum iron, Transferrin, C
Reactive Protein (CRP), erythropoietin, ferritin Serum Hepcidin and serum Cryptic LPI.
The blood samples will be obtained 3 hs after oral iron administration. The blood tests will
be collected at same time of necessary routine blood tests.
The serum will be collected at last 72 hs apart of clinical events: sepsis, NEC Necrotizing
Enterocolitis, Intra ventricular hemorrhage, severe illness and or blood transfusions.
Complete blood count including reticulocyte count and CHr (0.5 cc of blood in EDTA), will be
performed on a cell counter at Ha'Emek Medical Center laboratory.
Serum laboratory analyses 2.5 cc of blood will be centrifuged (no more than 2 h after
extraction) 0.25 cc of serum will be conserved at -700 C for the hepcidin analysis, 1 cc of
serum will be conserved at -700 C for the Cryptic LPI analysis.
Serum iron, Transferrin, C Reactive Protein (CRP), erythropoietin and ferritin analysis will
be performed at Ha'Emek Medical Center laboratory in the day of blood extraction immediately
after blood centrifugation ( 0.5 cc of serum).
Iron saturation will be calculated from serum iron and transferrin results. Serum hepcidin
will be measured by ELISA using the kit EIA-4705, DRG Instruments GmbH, Germany,
Frauenbergstr at Ha'Emek Medical Center laboratory following the kit instructions.
Serum Cryptic LPI will measured by Aferrix Ltd, Rehovot, Israel.
Serum samples will be obtained at 3 different times:
1. Before starting iron supplementation (maximum one week before).
2. At the beginning of iron supplementation in order to assess early signs of
erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).
3. Before discharge from hospitalization in order to asses the iron metabolism and sings of
iron deficiency (At least more than 2 weeks of supplementation).
Demographic and perinatal data will be collected, the data will include:
Ethnic origin, gender, gestational age, birth weight, Apgar score, adverse events during the
neonatal period including mechanical ventilation, infections, antibiotic therapy and
jaundice.
Number and amount of blood transfusions, Amount of blood obtained for routine analysis
calculated by the number of blood tests.
Time of introduction of enteral feeding, kind and daily amount of human milk or formula, and
amount of daily iron intake through diet.
Time of iron supplementation, dose change, days without iron supplementation will be
summarized. Accumulative amount of iron supplemented till discharge, calculated by mean iron
supplementation per day and per grams of weight gain will also summarized.
Follow-up of weight gain. Perinatal morbidity, and complications. Adverse reactions related
to iron treatment: skin rash, vomiting, bloody stools and NEC.
Maternal last red blood count before admission for delivery will be recorded. Maternal iron,
transferrin, ferritin level and Hb electrophoresis if present in maternal records,
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04423237 -
Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
|
||
Completed |
NCT04614779 -
Long-term Clinical Study of CN128 in Thalassemia Patients
|
Phase 2 | |
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT02833493 -
Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload
|
N/A | |
Completed |
NCT02164253 -
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
|
Phase 2 | |
Completed |
NCT00901199 -
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
|
Phase 2 | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Recruiting |
NCT00378469 -
Study of the Effects of Muscular Activity on Iron Metabolism
|
N/A | |
Completed |
NCT00117507 -
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
|
Phase 4 | |
Completed |
NCT00138684 -
Cytochrome P450 2E1 and Iron Overload
|
Phase 2 | |
Completed |
NCT03990181 -
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement
|
N/A | |
Terminated |
NCT02274233 -
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
|
Phase 1 | |
Completed |
NCT01546415 -
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
|
Phase 4 | |
Completed |
NCT01572818 -
Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients
|
N/A | |
Not yet recruiting |
NCT00980421 -
Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children
|
Phase 3 | |
Completed |
NCT01047098 -
Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation
|
N/A | |
Recruiting |
NCT05294471 -
Fully Automated High-Throughput Quantitative MRI of the Liver
|
||
Completed |
NCT03591575 -
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
|
Phase 4 | |
Active, not recruiting |
NCT00907283 -
Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
|
Phase 2 | |
Completed |
NCT01376622 -
Changes in Pituitary Iron and Volume With Deferasirox
|